by Raynovich Rod | Nov 13, 2017 | Biopharmaceuticals
Biotech Hangover from Earnings Clouds Outlook Healthcare sector (XLV) lagging technology (QQQ) and FAANG stocks. No earnings catalysts until Jan 2018 but Q4 has seen strong seasonality. Technicals rule as sellers predominate. Bull market is intact. On October 16 we...
by Raynovich Rod | Nov 6, 2017 | 2024 Rayno Biopharmaceuticals Portfolio
Update 11/8/17 …Per comments on Monday. Celgene (CELG) technicals are holding at $102-103 so we will add CELG to the Rayno Portfolio at a price of ~$102.5. The stock was battered on earnings news so we see good value and potential for long term growth. Forward...
by Raynovich Rod | Nov 1, 2017 | Biopharmaceuticals
BioBeat Market Update…Technicals Firming Up 11/3/17 11am A lot of green screen today so time to nibble but I would prefer to pick stocks rather than play the ETF game. Recent trades we made are: sell XBI at $87, buy PFE at $35 and today buy CELG at $100. No...
by Raynovich Rod | Oct 5, 2017 | Biopharmaceuticals
Speculation in Small Cap Biotech Picks Up-A Boon for Diligent Traders ETF Buying Is Driving All Small Cap and MicroCap Stocks Higher A Healthy Small Cap Rotation for Now: Reflation Trade ? Biotech stocks are rallying ahead of the expected strong seasonality in the...
by Raynovich Rod | Sep 22, 2017 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Biotech Bull Market: XBI is leader for 2017 and Over Five Years The FBT First Trust Arca Outperformed Up 157% Over Five Years In 2016 the Sector Underperformed After the 2015 Downdraft Here is our July 2013 review of several top Life Science Funds and ETFs . Over five...
by Raynovich Rod | Sep 14, 2017 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Markets Stable After Major FED Meeting: On Course for Gradual QT(Quantitative Tightening) FED to shrink assets by year end, 2 yr TSY up to 1.43% yield. Biotech stocks up slightly near September Top IBB $332.75, XBI $85.17. Large caps green: growth and value perceived:...
by Raynovich Rod | Aug 30, 2017 | Biopharmaceuticals
M&A Boosts Biotech Stocks For Third Day Gilead Sciences (GILD) and bluebird bio (BLUE) Both Soar Today Biotech Sector Back to 2017 Highs The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and...
by Raynovich Rod | Aug 7, 2017 | 2023-24 Life Science Portfolios, Clinical Diagnostics and Tools
8/10 Red Screen in the Morning We cautioned on XBI at $78 on 7/31 and today it broke through support at $75 to $74.70. ======= 8/9 Update After Close: A Bit of Caution after Trump’s “Fire and Fury” Talk Investors are holding off as global risks rise...
by Raynovich Rod | Aug 1, 2017 | Biopharmaceuticals
Rayno Large Cap Biopharma Earnings Summary 8/1/17 Biotech Stocks Hit Highs in Mid-July up 18%, 30% on XBI (Click on “urls” below for Company Press Release) All the large cap biopharmaceutical earnings have come in except Regeneron (REGN) which will report...
by Raynovich Rod | Jul 25, 2017 | Biopharmaceuticals
Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and...